Dog Prostatic Hyperplasia Surgical and Medical Options

Benign prostatic hyperplasia in intact male dogs responds well to both surgical castration and medical management, with treatment choice affecting long-term welfare outcomes.

Key Facts

Castration remains the most reliable and permanent treatment for BPH, with prostatic regression within weeks
Osaterone acetate (Ypozane) is a licensed anti-androgen that reduces prostatic size effectively for several months
Finasteride (a 5-alpha reductase inhibitor) can reduce prostatic size in some dogs with fewer side effects
Medical management requires ongoing treatment as the prostate regrows when medication is discontinued
Concurrent prostatic cysts or abscesses may require surgical drainage alongside medical or castration management

Welfare Considerations

The welfare outcomes of BPH treatment depend on treatment completeness and any complications. Castration provides permanent resolution with a single procedure — the prostate atrophies to a small fraction of its enlarged size within 4-8 weeks, permanently relieving constipation, urinary difficulty, and prostatic discomfort. Medical management provides good temporary relief but requires repeated treatment and monitoring. For dogs intended for breeding, osaterone acetate provides a welfare-appropriate interim management while preserving breeding capacity. Dogs with concurrent prostatic abscesses face the additional welfare burden of systemic sepsis requiring urgent surgical drainage alongside castration.

What You Can Do

Choose treatment based on breeding plans, general anaesthetic risk, and financial circumstances in discussion with your veterinarian
Follow up medical treatment with regular prostatic size assessment to confirm ongoing therapeutic effect
Consider castration as the definitive welfare-optimal treatment in dogs not intended for future breeding
Monitor for prostatic abscess signs including fever, straining, and bloody urethral discharge requiring urgent veterinary care